[Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma].
The changes in serum CA125, CA19-9, CEA, Ferritin, TPA, IAP and LDH concentrations were measured in 22 primary cases and 7 recurrent cases of adenocarcinoma of the uterine cervix and endometrial carcinoma in order to examine the clinical usefullness of CA125 and CA19-9 as a tumor marker. Localization of CA125 and CA19-9 was also examined in adenocarcinoma, normal endocervix and endometrium immunohistochemically. 1. Twenty-seven percent of primary cases had increased serum CA125 and CA19-9 which decreased rapidly after operation or chemotherapy, reflecting reduction of the tumor mass. 2. In these cases, CA125 or CA19-9 was localized in carcinoma tissues immunohistochemically. On the other hand, in normal endocervical and endometrial glands, CA125 was localized, but CA19-9 was not. 3. In most recurrent cases, serum CA125 and CA19-9 increased early and markedly, compared with the other markers. 4. The change in serum Ferritin, CEA, TPA, IAP and LDH didn't reflect clinical courses such as operation and chemotherapy. In recurrent cases they increased even more slowly and slightly than CA125 or CA19-9. These results show that CA125 and CA19-9 are useful tumor markers in the management of adenocarcinoma of the uterine cervix and endometrial carcinoma, especially in advanced or recurrent cases.